{"id":537,"date":"2022-09-06T05:38:33","date_gmt":"2022-09-06T05:38:33","guid":{"rendered":"https:\/\/bioxxmed.ag\/?page_id=537"},"modified":"2026-04-27T09:42:00","modified_gmt":"2026-04-27T09:42:00","slug":"home","status":"publish","type":"page","link":"https:\/\/bioxxmed.ag\/en\/","title":{"rendered":"Home"},"content":{"rendered":"
\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\tBiomedicine is the window into the future of medicine. Biomedicine relies on the molecular and cell biological building blocks to identify and prevent diseases. Nanotechnology, biotechnology, as well as digital solutions open up innovative and tailored therapeutic options for new drugs or medical devices. These promising approaches offer great potential for investors looking for investments in a dynamic future market.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
Global health and access to modern medical treatment is one of the greatest challenges facing our societies. Biomedicine is the answer on the way to individualised medicine - with therapeutic innovations for the general public. Biomedicine is therefore an ideal asset for investors who, in addition to the economic success of their investment, are looking for an ethical-ecological investment with sustainable impact.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t Nach dem vollendeten Verkauf der Tochtergesellschaft Rancoderm GmbH im M\u00e4rz 2026 besitzt die Gesellschaft aktuell keine aktiven Projekte. F\u00fcr die Zukunft ist es beabsichtigt in neue innovative Projekte zu investieren – sollte es notwendig werden dazu auch durch Kapitalerh\u00f6hungen und \/ oder der Gewinnung weiterer Investoren die erforderlichen Mittel zu generieren. <\/p> Die bioXXmed AG widmet sich aktuell der \u00dcberwachung des Fortschritts bei der verkauften Beteiligung an der Rancoderm GmbH, w\u00e4hrend parallel Ausschau nach Investitionsm\u00f6glichkeiten f\u00fcr ein neues operatives Gesch\u00e4ft gehalten wird.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\tSustainable<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
Financial investments<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
for maximum success<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\tAktueller Status<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t